Syndax Pharmaceuticals Inc., a Waltham, MA-based developer of epigenetic therapies for treatment-resistant cancers, secured a $26.6m Series B financing.
Backers included Domain Associates, MPM Capital, Forward Ventures and RusnanoMedInvest (RMI).
Led by Arlene M. Morris, chief executive officer, Syndax holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor in late-stage clinical development for the treatment of advanced breast cancer and lung cancer.
The company intends to use the funds to continue advancement of its late-stage pipeline of epigenetic-based combination therapies for treatment-resistant cancers, including activities in preparation for an NDA-enabling Phase 3 study of entinostat in metastatic breast cancer. The study is currently being developed by the ECOG-ACRIN Cancer Research Group, which would conduct the study under the sponsorship of the Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI).
Founded in 2007, Syndax has raised $81.6m.